PubRank

A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

Clinical Trial ID NCT01163799

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01163799

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005 27.17
2 Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995 10.04
3 Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 5.67
4 Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007 5.39
5 Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2003 4.12
6 Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004 3.78
7 Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995 3.64
8 IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007 3.31
9 Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol 1991 2.93
10 Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci U S A 2007 2.92
11 Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2002 2.83
12 A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008 2.26
13 Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002 2.18
14 American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006 2.11
15 Cutting edge: Phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol 2009 1.73
16 The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 2006 1.56
17 Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001 1.54
18 Retracted Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002 1.52
19 Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993 1.51
20 Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol 2002 1.50
21 Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998 1.47
22 Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 2008 1.44
23 A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002 1.33
24 Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2006 1.25
25 Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol 2002 1.23
26 Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994 1.23
27 Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions. J Immunol 2001 1.22
28 Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol 1999 1.20
29 Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol 1997 1.20
30 CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection. J Immunol 2000 1.15
31 Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002 1.14
32 A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005 1.14
33 Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med 2007 1.14
34 IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant 2005 1.13
35 Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl 2009 1.13
36 Circulating CD2+ monocytes are dendritic cells. J Immunol 1999 1.07
37 Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci U S A 2009 1.06
38 Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 2003 1.01
39 Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival. Transplant Proc 1999 0.93
40 CD2+/CD14+ monocytes rapidly differentiate into CD83+ dendritic cells. Eur J Immunol 2003 0.91
41 Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000 0.90
42 Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000 0.89
43 Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003 0.88
44 Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol 1995 0.87
45 Predominant infiltration of rejecting human renal allografts with T cells expressing CD8 and CD45RO. Transplantation 1995 0.84
46 Interleukin-17 and kidney allograft outcome. Transplant Proc 2009 0.82
47 Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001 0.81
48 Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation 1996 0.80
49 BTI-322 for acute rejection after renal transplantation. Transplant Proc 1997 0.80
50 The arduous road to achieving an immunosuppression-free state in kidney transplant recipients. Nat Clin Pract Nephrol 2007 0.79
51 BTI-322 for induction therapy after renal transplantation: a randomized study. Transplant Proc 1997 0.78
52 The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates. Ther Immunol 1994 0.78
53 An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2005 0.78
54 Prevention of rejection with BTI-322 after renal transplantation (results at 9 months). Transplant Proc 1997 0.76
55 Differential expression of cell surface antigens on subsets of CD4+ and CD8+ T cells. Med Sci Monit 2004 0.75
56 Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. Transplantation 2005 0.75
Next 100